Mirum Pharma insider files to sell 842 shares

Mirum Pharmaceuticals, Inc. insider Jolanda Howe filed a notice to sell restricted shares under Rule 144.

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. insider Jolanda Howe filed a notice to sell restricted shares under Rule 144. The filing covers the proposed sale of 842 shares of common stock, with an aggregate market value of 81606.64, through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on NASDAQ.

The 842 shares were acquired on 01/23/2026 as restricted stock units vesting under a registered compensation plan for services to the issuer. The filing notes that 926 shares of common stock were sold on 01/22/2026 for gross proceeds of 86419.16, and that 51393574 shares of common stock were outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Mirum Pharmaceuticals (MIRM)?

The Form 144 discloses that insider Jolanda Howe plans to sell 842 shares of Mirum Pharmaceuticals common stock under Rule 144. The shares will be sold through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on the NASDAQ exchange.

How many Mirum Pharmaceuticals (MIRM) shares are planned for sale and at what market value?

The filing covers a proposed sale of 842 shares of Mirum Pharmaceuticals common stock. These shares are shown with an aggregate market value of 81606.64. The transaction is to be executed through Morgan Stanley Smith Barney LLC on or about 01/26/2026.

How did the insider acquire the Mirum Pharmaceuticals (MIRM) shares being sold?

The 842 Mirum Pharmaceuticals shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan. The filing states they were received from the issuer as compensation for services, rather than through a cash purchase or open-market transaction.

What recent Mirum Pharmaceuticals (MIRM) share sales by the insider are disclosed?

The filing reports that Jolanda Howe sold 926 shares of Mirum Pharmaceuticals common stock on 01/22/2026. Those sales generated gross proceeds of 86419.16. This disclosure covers all securities of the issuer sold during the past three months by the same seller.

How many Mirum Pharmaceuticals (MIRM) shares are outstanding in this Form 144?

The notice states that 51393574 shares of Mirum Pharmaceuticals common stock were outstanding. This figure provides context for the planned sale of 842 shares under Rule 144, indicating the overall size of the company’s equity base at the time referenced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 06:47 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001974200
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MIRUM PHARMACEUTICALS, INC.
SEC File Number	001-38981
Address of Issuer	989 E HILLSDALE BLVD., SUITE 300 FOSTER CITY CALIFORNIA 94404
Phone	650-667-4085
Name of Person for Whose Account the Securities are To Be Sold	Jolanda Howe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	842	81606.64	51393574	01/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	Restricted Stock Units vesting under registered plan	Issuer			842	01/23/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jolanda Howe c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	926	86419.16

144: Remarks and Signature

Remarks	This is a sell-to-cover transaction for taxes owed related to recent vesting of stock unit awards granted by the Issuer.
Date of Notice	01/28/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/23/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jolanda Howe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)